For HLRCC they did not adhereto the strategy of expectant management for tumors less than 3 cm, as wepreviously described for other hereditary kidney cancer syndromes, such as VHL,HPRC, or BHD [2, 19, 28]. This evidence concerns the gene VHL and hereditary leiomyomatosis and renal cell cancer.